Cynosure recently announced that SculpSure has received marketing approval from the Korean Ministry of Food and Drug Safety (MFDS) for non-invasive lipolysis of the abdomen and flanks.
"MFDS approval of SculpSure is another major step in our international growth strategy for this breakthrough non-invasive fat-reduction treatment," Michael Davin, President and CEO of Cynosure, said. "As one of the world's fastest-growing medical aesthetic regions, the Asia Pacific market is an important one for SculpSure and our entire product portfolio. Our Asia-Pac subsidiaries made up 43 percent of our international product revenue in the first half of this year, compared with 33 percent in the same period of 2015. We look forward to showcasing SculpSure at the IMCAS Asia 2016 meeting later this week in Taipei."
SculpSure has been proven as a safe and effective treatment designed to eliminate 24 percent of treated fat in a procedure that lasts for a duration of 25 minutes that does not require downtime and allows patients continue normal activities as soon as the procedure is over. SculpSure is not recommended for those who have a BMI (body mass index) of over 30.